TABLE 1.
Baseline clinical characteristics of SCLC patients
| Variable | Total (n = 30) (100%) | STINGpos (n = 6) (20%) | STINGneg (n = 24) (80%) | p value |
|---|---|---|---|---|
| Age | ||||
| Median (y) | 64.5 (50–90) | 71 (63–90) | 62 (50–82) | |
| <65 | 15 (50) | 1 (16.7) | 14 (58.3) | 0.171 |
| ≥65 | 15 (50) | 5 (83.3) | 10 (41.7) | |
| Gender | ||||
| Male | 29 (96.7) | 6 (100) | 23 (95.8) | |
| Female | 1 (3.3) | 0 (0) | 1 (4.2) | |
| Stage | 0.424 | |||
| Limited stage | 6 (20) | 0 (0) | 6 (25) | |
| Extensive stage | 24 (80) | 6 (100) | 18 (75) | |
| Tumor size | ||||
| ≤5 cm | 10 (33.3) | 1 (16.7) | 9 (37.5) | |
| >5 cm | 13 (43.3) | 4 (66.7) | 9 (37.5) | |
| Unknown | 7 (23.3) | 1 (16.7) | 6 (25) | |
| TNM stage | ||||
| I | 0 (0) | 0 (0) | 0 (0) | |
| II | 1 (3.3) | 0 (0) | 1 (4.2) | |
| III | 8 (26.7) | 1 (16.7) | 7 (29.2) | |
| IV | 21 (70) | 5 (83.3) | 16 (66.7) | |
| T stage | ||||
| T1 | 0 (0) | 0 (0) | 0 (0) | |
| T2 | 2 (6.7) | 0 (0) | 2 (8.3) | |
| T3 | 2 (6.7) | 0 (0) | 2 (8.3) | |
| T4 | 26 (86.7) | 6 (100) | 20 (83.3) | |
| N stage | 0.849 | |||
| N1 | 1 (3.3) | 0 (0) | 1 (4.2) | |
| N2 | 18 (60) | 4 (66.7) | 14 (58.3) | |
| N3 | 11 (36.7) | 2 (33.3) | 9 (37.5) | |
| M stage | 0.765 | |||
| M0 | 9 (30) | 1 (16.7) | 8 (33.3) | |
| M1 | 21 (70) | 5 (83.3) | 16 (66.7) | |
| TTF‐1 | 0.156 | |||
| — | 4 (13.3) | 1 (16.7) | 3 (12.5) | |
| 1+ | 14 (46.7) | 5 (83.3) | 9 (37.5) | |
| 2+ | 2 (6.7) | 0 (0) | 2 (8.3) | |
| 3+ | 10 (33.3) | 0 (0) | 10 (41.7) | |
| Syn | 0.547 | |||
| — | 0 (0) | 0 (0) | 0 (0) | |
| 1+ | 20 (66.7) | 5 (83.3) | 15 (62.5) | |
| 2+ | 3 (10) | 0 (0) | 3 (12.5) | |
| 3+ | 7 (23.3) | 1 (16.7) | 6 (25) | |
| CgA | 0.227 | |||
| — | 1 (3.3) | 1 (16.7) | 0 (0) | |
| 1+ | 22 (73.3) | 4 (66.7) | 18 (75) | |
| 2+ | 1 (3.3) | 0 (0) | 1 (4.2) | |
| 3+ | 6 (20) | 1 (16.7) | 5 (20.8) | |
| CD56 | ||||
| — | 1 (3.3) | 1 (16.7) | 0 (0) | |
| 1+ | 9 (30) | 3 (50) | 6 (25) | |
| 2+ | 1 (3.3) | 0 (0) | 1 (4.2) | |
| 3+ | 9 (30) | 0 (0) | 9 (37.5) | |
| Unknown | 10 (33.3) | 2 (33.3) | 8 (33.3) | |
| CK | ||||
| — | 0 (0) | 0 (0) | 0 (0) | |
| 1+ | 16 (53.3) | 5 (83.3) | 11 (45.8) | |
| 2+ | 2 (6.7) | 0 (0) | 2 (8.3) | |
| 3+ | 3 (10) | 1 (16.7) | 2 (8.3) | |
| Unknown | 9 (30) | 0 (0) | 9 (37.5) | |
Note: Values were shown as n (%) unless otherwise noted. p‐value: Fisher exact test. Characteristics with unequal distribution and too many missing data were not assessed in statistical analysis.
Abbreviation: CK, cytokeratin.